Amy Peterson - Concepedia

Author

Amy Peterson

Also Known As

A C Peterson, A Peterson, A. C. Peterson, A. Peterson, Amy C Peterson, Amy C. Peterson, Amy Christian Peterson, Amy Peterson, Amy C. Peterson, Peterson, Amy

115

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

University of Chicago Memorial Sloan Kettering Cancer Center Texas A&M University May Institute Colorado State University

About

Amy Peterson is an author at University of Chicago specializing in medicine, immunology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1K
2	Cell Biology	3	3	420
3	Public Health	1	1	38
4	Allergy	1	1	38
5	Genetic Medicine	1	1	38

Amy Peterson

Publications

Citations

H-Index

Page 1

	Year	Citations
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment Helena Harlin, Yuru Meng, Amy Peterson, Cancer Research	2009	1.1K
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells Christian U. Blank, Ian E. Brown, Amy Peterson, Cancer Research	2004	766
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer David R. Spigel, Thomas J. Ervin, Rodryg Ramlau, Journal of Clinical Oncology	2013	474
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-α Yuanyuan Zha, Reinhard Marks, Allen W. Ho, Nature Immunology T Cell AnergySignal TransductionImmune Cell DevelopmentImmunologyImmune Regulation	2006	264
Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. David R. Spigel, Thomas J. Ervin, Rodryg Ramlau, Journal of Clinical Oncology Advanced NsclcFinal Efficacy ResultsOncologyClinical TherapeuticMetronomic Therapy	2011	194
Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections Nydiaris Hernández‐Santos, Anna R. Huppler, Amy Peterson, Mucosal Immunology Mucosal ImmunologyMicrobial PathogensAdaptive Immune SystemPathogenesisImmunology	2012	188
Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma Amy Peterson, Helena Harlin, Thomas F. Gajewski Journal of Clinical Oncology	2003	152
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley, Journal of Clinical Oncology Androgen ReceptorBreast OncologyPathologyPharmacotherapyAr Inhibitor	2015	149
Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites Helena Harlin, Todd V. Kuna, Amy Peterson, Cancer Immunology Immunotherapy Malignant Melanoma AscitesCancer ImmunosurveillanceMelanomaImmunologyTumor Progression	2006	142
Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit Hartmut Koeppen, Wei Yu, Jiping Zha, Clinical Cancer Research	2014	131

Page 1